MRK Merck & Co., Inc.

132.73USD-3.67%Mkt Cap: 327.41B USDP/E: 134.15

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxi…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap327.41B USD
Enterprise Value383.97B USD
Revenue (TTM)67.38B USD
Gross Profit48.63B USD
Net Income (TTM)18.25B USD
Revenue/Share27.24 USD
Last Price132.73 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees73.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—
Valuation
P/E (Trailing)134.15
P/E (Forward)14.81
PEG3.33
EV/EBITDA13.02
EV/Revenue5.70
P/S4.86
P/B7.30
EPS (TTM)1.00 USD
EPS (Forward)8.98 USD
52W Range
92.1163% of range156.92
52W High156.92 USD
52W Low92.11 USD
Profitability
Gross Margin74.80%
Oper. Margin35.16%
EBITDA Margin43.77%
Profit Margin28.08%
ROE34.70%
ROA13.34%
ROIC21.92%
ROCE20.37%
Growth
Revenue Growth4.70%
Earnings Growth-12.00%
Cash Flow & Leverage
Operating CF16.47B USD
CapEx (TTM)4.11B USD
FCF Margin20.81%
FCF Yield4.28%
Net Debt44.25B USD
Net Debt/EBITDA1.50
Net Debt/FCF3.16
Balance Sheet
Debt/Equity0.94
Current Ratio1.35
Quick Ratio0.81
Book Value/Sh18.20 USD
Cash/Share3.91 USD
Dividends
Fwd Div Rate3.40 USD
Trail. Div Rate3.36 USD
Div. Yield2.55%
5Y Avg Yield2.87%
Payout Ratio343.43%
Ex-Div DateSep 15, 2026
Pay DateOct 7, 2026
Splits
Last Split1048:1000
Split DateJun 3, 2021
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)161.53 USD
Upside (mean)+21.7%
Target Range105.00 USD – 186.00 USD
105.00+21.7% to mean186.00
# Analysts26
Ownership
Shares Out.2.47B
Float2.46B
Insiders0.11%
Institutions82.10%
Short Interest
Short Ratio2.6d
Short % Float1.08%
Short % Out.1.08%
Shares Short26.60M
Short (prev mo.)28.27M
Technical
SMA 50146.02 (-9.1%)
SMA 200128.82 (+3.0%)
Beta0.12
S&P 52W Chg12.08%
Avg Vol (30d)9.05M
Avg Vol (10d)7.95M
Technical Indicators
RSI (14)31.8
MACD-1.4876
MACD Signal-0.0860
MACD Hist.-1.4016
BB Upper153.63 USD
BB Middle144.93 USD
BB Lower136.22 USD
BB Width12.01%
ATR (14)4.518 USD
Vol Ratio (20d)1.53x

About Merck & (NYSE: MRK)

›

Merck & (NYSE: MRK) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 73,000 employees.

The shares were at 132.73 USD on 19 November 2026, up 45.1% over 52 weeks. Its 52-week range is 92.11 USD to 156.92 USD: the price is 15.4% below the high and 44.1% above the low.

At a market capitalisation of 327.41B USD, it trades at 134.2 times trailing earnings and 14.8 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 25.4, a premium of 427% for MRK. It pays a dividend yielding 2.55%, against a median of 2.43% among the dividend payers in that peer group.

Merck & reports return on equity of 34.7%, an operating margin of 35.2% and revenue up 4.7% year over year.

Its debt exceeds its cash by 44.25B USD, a debt-to-equity ratio of 0.94. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 26 analysts cover the stock, with an average rating of Buy; their mean price target of 161.53 USD is 21.7% above the current price. The next earnings report is expected on 2 February 2027.